Table 3.
Genotypic and allelic distributions of TPH2 and 5-HT2A polymorphisms of MDD patients and controls.
| Gene | SNP | Sample | Genotype (%) | p | Allele (%) | p | Odds ratio (95%CI) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| TPH2 | rs4570625 | GG | TG | TT | G | T | ||||
| Case | 73 (26.3) | 131 (47.1) | 74 (26.6) | 0.129 | 277 (49.8) | 279 (50.2) | 0.079 | 1.233 | ||
| Control | 55 (19.2) | 146 (50.9) | 86 (29.9) | 256 (44.6) | 318 (55.4) | (0.976–1.558) | ||||
| rs11178997 | AA | AT | TT | A | G | |||||
| Case | 93 (33.5) | 170 (61.1) | 15 (5.4) | 0.000* | 356 (64.0) | 200 (36.0) | 0.000* | 1.637 | ||
| Control | 135 (47.0) | 29 (10.1) | 123 (42.9) | 299 (52.1) | 275 (47.9) | (1.290–2.078) | ||||
| rs120074175 | AA | AG | GG | A | T | |||||
| Case | 207 (74.5) | 48 (17.2) | 23 (8.3) | 0.000* | 462 (83.1) | 94 (16.9) | 0.000* | 7.909 | ||
| Control | 108 (37.6) | 4 (1.4) | 175 (61.0) | 220 (38.3) | 354 (61.7) | (5.987–10.447) | ||||
| 5-HT2A | rs7997012 | AA | AG | GG | A | G | ||||
| Case | 22 (7.9) | 106 (38.1) | 150 (54.0) | 0.247 | 150 (27.0) | 406 (73.0) | 0.257 | 1.167 | ||
| Control | 13 (4.5) | 112 (39.0) | 162 (56.5) | 138 (24.0) | 436 (76.0) | (0.893–1.526) | ||||
| rs6311 | TT | CT | CC | T | C | |||||
| Case | 82 (29.5) | 128 (46.0) | 68 (24.5) | 0.029 | 292 (52.5) | 264 (47.5) | 0.662 | 1.053 | ||
| Control | 65 (22.6) | 164 (57.2) | 58 (20.2) | 294 (51.2) | 280 (48.8) | (0.834–1.330) | ||||
| rs6313 | TT | CT | CC | T | C | |||||
| Case | 79 (28.4) | 129 (46.4) | 70 (25.2) | 0.049 | 287 (51.6) | 269 (48.4) | 0.847 | 1.023 | ||
| Control | 65 (22.6) | 163 (56.8) | 59 (20.6) | 293 (51.0) | 281 (49.0) | (0.810–1.292) | ||||
Bolded indicates statistically significant (p < 0.05).
*
indicates the difference was still significant after Bonferroni correction.